In a different study, the anti-tumour efficacy of an anti-PD-1 scFV HSV OV was improved by the addition of systemic TIGIT ICI therapy, as evidenced by increased splenic tumour-specific CD8 T cells [76]. Here, CD8A is linked to neoplasm.